Basel, Switzerland, 14 December 2017 — Lonza announced today that its integrated development and manufacturing site for biopharmaceutical liquid - filled hard capsules in Edinburgh (UK) has new
anti-counterfeiting security capabilities in place and is in full compliance with EU and U.S. regulatory requirements for serialization.